Regulation And Legal
Merck Gets FDA Priority Review, Bladder Cancer
Merck announced FDA granted priority review for KEYTRUDA and KEYTRUDA QLEX combined with Padcev for muscle‑invasive bladder cancer.
The FDA set a target action date of August 17, 2026 for the two supp
